Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02759289 · ClinicalTrials.gov registry record
Arsenic, Disordered Glucose Homeostasis and Atherosclerosis
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 279
- Enrollment target
NCT02759289: Completed study, sponsored by NYU Langone Health.
NCT02759289 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 279 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02759289 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 279 participants
- Enrollment target
Study Summary
Investigators will recruit 250 subjects; Group A will consist of 100 prediabetic patients with an A1c of 5.7%-6.4%. Group B will consist of 100 patients with uncontrolled T2D defined as either a) an A1c of 6.5%-7.9% without diabetes medications or b) an A1c ≥ 8.0% with or without diabetes medications. Group C will include 50 participants without T2D or known cardiovascular disease to serve as control comparisons.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2015-11 |
| Est. Completion | 2020-09-15 |
What the finished NCT02759289 record still lists
NCT02759289 is an observational study that tracks outcomes without assigning an intervention. The registered 279 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02759289 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02759289 about?
NCT02759289 is a clinical study titled "Arsenic, Disordered Glucose Homeostasis and Atherosclerosis". Investigators will recruit 250 subjects; Group A will consist of 100 prediabetic patients with an A1c of 5.7%-6.4%. Group B will consist of 100 patients with uncontrolled T2D defined as either a) an A1c of 6.5%-7.9% without diabetes medications or b) an A1c ≥ 8.0% with or without diabetes medication...
What is the current status of trial NCT02759289?
This trial is currently completed. The enrollment target is 279 participants. The study started on 2015-11. Estimated completion is 2020-09-15.
Who is sponsoring clinical trial NCT02759289?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04783857 · 279 participants · Phase 4
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
- NCT05407324 · 279 participants · Phase 2
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
- NCT06299748 · 279 participants
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
- NCT06582784 · 279 participants · NA
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia